Tagrisso
J&J’s drug combo challenges AZ’s Tagrisso in lung cancer, but faces hurdles
Anika Sharma
In a high-stakes battle, Johnson & Johnson’s drug combination of Rybrevant and the Lazertinib, developed in partnership with Yuhan, has ...
AstraZeneca’s Tagrisso dominates lung cancer market with projected $7B sales by 2025
Anika Sharma
The lung cancer drug market has been notably dominated by antibodies and immunotherapies, but a recent report from GlobalData suggests ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Anika Sharma
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
J&J’s Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
Anika Sharma
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
